Literature DB >> 11122262

In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG).

Y M van der Geld1, M G Huitema, C F Franssen, R van der Zee, P C Limburg, C G Kallenberg.   

Abstract

T cell-mediated immunity is thought to play an important role in the pathogenesis of WG. In previous studies a minority of WG patients as well as some healthy controls showed in vitro proliferation of their peripheral blood mononuclear cells (PBMC) to PR3, the main autoantigen in WG. The relevant peptides responsible for this in vitro proliferation have not been identified. In order to define immunogenic peptides, PBMC of 13 WG patients in remission and 10 healthy controls were tested for proliferation to linear peptides of PR3 and to whole PR3. Fifty overlapping peptides spanning the whole PR3 sequence were synthesized. Peptides were tested in pools of five peptides and as single peptide. PBMC of two WG patients and one healthy control proliferated to whole PR3 and to peptide pools. In addition, 10 WG patients and eight healthy controls that did not proliferate to whole PR3 did proliferate to pools of PR3 peptides. Although more WG patients tended to react to particular peptide pools, no significant difference was seen between lymphocyte proliferation to PR3 peptides of WG patients and that of healthy controls. The pools of peptides recognized were mainly located at the N- and C-terminus of PR3. No correlation was observed between HLA type and proliferation on particular peptide pools. No proliferation of PBMC was observed to single peptides. In conclusion, T cells of WG patients proliferate in vitro more frequently to PR3 peptides than to the whole PR3 protein. Peptides derived from the signal sequence, the propeptide or peptides located at the C-terminus of PR3 induce highest levels of proliferation. No specific PR3 sequence could be identified that was preferentially recognized by PBMC of WG patients compared with controls.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122262      PMCID: PMC1905800          DOI: 10.1046/j.1365-2249.2000.01415.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation.

Authors:  O Olerup; H Zetterquist
Journal:  Tissue Antigens       Date:  1992-05

2.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.

Authors:  R Y Leavitt; A S Fauci; D A Bloch; B A Michel; G G Hunder; W P Arend; L H Calabrese; J F Fries; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

Review 3.  Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis.

Authors:  J W Tervaert; R Goldschmeding; J D Elema; M van der Giessen; M G Huitema; G K van der Hem; T H The; A E von dem Borne; C G Kallenberg
Journal:  Kidney Int       Date:  1990-02       Impact factor: 10.612

4.  Wegener autoantigen and myeloblastin are encoded by a single mRNA.

Authors:  C Labbaye; P Musette; Y E Cayre
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

5.  Serum markers of T cell activation in relapses of Wegener's granulomatosis.

Authors:  C A Stegeman; J W Tervaert; M G Huitema; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

6.  T cell response to myelin basic protein epitopes in multiple sclerosis patients and healthy subjects.

Authors:  R Liblau; E Tournier-Lasserve; J Maciazek; G Dumas; O Siffert; G Hashim; M A Bach
Journal:  Eur J Immunol       Date:  1991-06       Impact factor: 5.532

7.  T and B cell responses to neutrophil cytoplasmic antigens in systemic vasculitis.

Authors:  P W Mathieson; C M Lockwood; D B Oliveira
Journal:  Clin Immunol Immunopathol       Date:  1992-05

8.  Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders.

Authors:  E Brouwer; J W Tervaert; G Horst; M G Huitema; M van der Giessen; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

9.  Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity.

Authors:  W H Schmitt; C Heesen; E Csernok; A Rautmann; W L Gross
Journal:  Arthritis Rheum       Date:  1992-09

10.  Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex class II-restricted T cells.

Authors:  L Adorini; J Moreno; F Momburg; G J Hämmerling; J C Guéry; A Valli; S Fuchs
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

3.  ANCA patients have T cells responsive to complementary PR-3 antigen.

Authors:  Jiajin Yang; David J Bautz; Sofia Lionaki; Susan L Hogan; Hyunsook Chin; Roland M Tisch; John L Schmitz; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

4.  Analysis of T-cell receptor usage in myeloperoxidase--antineutrophil cytoplasmic antibody-associated renal vasculitis.

Authors:  Kouichi Hirayama; Takashi Ishizu; Homare Shimohata; Yasunori Miyamoto; Tomoko Kakita; Miho Nagai; Yujiro Ogawa; Shogo Fujita; Aki Hirayama; Kunihiro Yamagata; Masaki Kobayashi; Akio Koyama
Journal:  Clin Exp Nephrol       Date:  2009-10-07       Impact factor: 2.801

5.  Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis.

Authors:  S Marinaki; I Neumann; A-I Kälsch; P Grimminger; A Breedijk; R Birck; W Schmitt; R Waldherr; B A Yard; F J Van Der Woude
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

6.  Immunological Interaction of HLA-DPB1 and Proteinase 3 in ANCA Vasculitis is Associated with Clinical Disease Activity.

Authors:  Dhruti P Chen; Elizabeth A McInnis; Eveline Y Wu; Katherine G Stember; Susan L Hogan; Yichun Hu; Candace D Henderson; Lauren N Blazek; Simon Mallal; Edita Karosiene; Bjoern Peters; John Sidney; Eddie A James; William W Kwok; J Charles Jennette; Dominic J Ciavatta; Ronald J Falk; Meghan E Free
Journal:  J Am Soc Nephrol       Date:  2022-06-07       Impact factor: 14.978

7.  Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.

Authors:  Marta Christensson; Erna Pettersson; Kjell Eneslätt; Birger Christensson; Johan Bratt; Solbritt Rantapää-Dahlqvist; Karl-Gösta Sundqvist
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

8.  Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis.

Authors:  A R Clayton; C O S Savage
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

9.  Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology.

Authors:  Agnieszka A Rarok; Ymke M van der Geld; Coen A Stegeman; Pieter C Limburg; Cees G M Kallenberg
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

10.  Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.

Authors:  Peter A Merkel; Gang Xie; Paul A Monach; Xuemei Ji; Dominic J Ciavatta; Jinyoung Byun; Benjamin D Pinder; Ai Zhao; Jinyi Zhang; Yohannes Tadesse; David Qian; Matthew Weirauch; Rajan Nair; Alex Tsoi; Christian Pagnoux; Simon Carette; Sharon Chung; David Cuthbertson; John C Davis; Paul F Dellaripa; Lindsy Forbess; Ora Gewurz-Singer; Gary S Hoffman; Nader Khalidi; Curry Koening; Carol A Langford; Alfred D Mahr; Carol McAlear; Larry Moreland; E Philip Seo; Ulrich Specks; Robert F Spiera; Antoine Sreih; E William St Clair; John H Stone; Steven R Ytterberg; James T Elder; Jia Qu; Toshiki Ochi; Naoto Hirano; Jeffrey C Edberg; Ronald J Falk; Christopher I Amos; Katherine A Siminovitch
Journal:  Arthritis Rheumatol       Date:  2017-04-06       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.